Table 1.
Patient demographic and clinical characteristics
| Characteristic | Sunitinib (N = 64) |
|---|---|
| Median (range) age, years |
52 (36–70) |
| ECOG performance status, n (%) |
|
| 0 |
24 (38) |
| 1 |
40 (63) |
| Histologic type, n (%) |
|
| Ductal |
54 (84) |
| Inflammatory |
4 (6) |
| Other |
6 (9) |
| Receptor status, n (%) |
|
| ER-positive |
37 (58) |
| PgR-positive |
26 (41) |
| HER2-positive |
12 (19) |
| Triple-negative |
20 (31) |
| Metastatic sites, n (%) |
|
| Lymph nodes |
41 (64) |
| Liver |
38 (59) |
| Lung |
31 (48) |
| Bone |
25 (39) |
| Pleural effusion |
17 (27) |
| Local recurrence |
16 (25) |
| Skin |
14 (22) |
| Primary tumor |
4 (6) |
| Prior systemic therapy,* n (%) |
64 (100) |
| Anthracycline + taxane + other |
60 (94) |
| Anthracycline + taxane |
1 (2) |
| Anthracycline + other |
2 (3) |
| Other | 1 (2) |
Adapted from Burstein HJ, et al.: J Clin Oncol 2008, 26(11):1810–1816 [15] with permission. © 2008 American Society of Clinical Oncology. All rights reserved. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR, progesterone receptor. *Eight patients (13%) also received prior trastuzumab treatment.